Global Ultrasound Probe Disinfection Market Research Report 2023-2027: Increasing Adoption of Automated High-Level Disinfection Systems Influencing growth

The “Ultrasound Probe Disinfection Market by Product (Instrument, Services, Consumables (Disinfectants & Detergents)), Probe Type (Linear, Convex, & TEE Transducers),Process (High-Level & Low-Level Disinfection), End User (Hospitals) – Global Forecast to 2027” report has been added to’s offering.

The global market for disinfecting ultrasound probes is poised to experience significant growth, with a projected value of USD 936 million by 2027, up from USD 501 million in 2022, representing a robust CAGR of 13.3%

This comprehensive report delves into the ultrasound probe disinfection market, aiming to assess its size and future growth potential by examining various segments, including product types, processes, probe types, end users, and regions. Additionally, the report offers a product portfolio matrix showcasing the variety of ultrasound probe disinfectants available. A competitive analysis of key market players is also included, complete with their company profiles, product offerings, and key strategies.

The market’s expansion is primarily driven by the rising incidence of hospital-acquired infections (HAIs), attributed to inadequate reprocessing of ultrasound probes, along with stringent government regulations and guidelines in developed markets. Nonetheless, the market faces growth constraints due to the reluctance to transition from manual disinfection methods to automated probe reprocessing.

Within this market landscape, consumables emerge as a pivotal segment, benefiting from the growing demand for high-level disinfectants for critical and semi-critical ultrasound probes. They also require relatively modest capital investment for adoption in healthcare and diagnostic centers. Furthermore, the high-level disinfection process segment continues to dominate, aligning with the increasing regulatory standards and the demand for automated disinfection systems.

North America is anticipated to seize the largest share of the ultrasound probe disinfection market in 2022. Factors driving this regional dominance include the presence of major market players, rising healthcare expenditures, and a well-established regulatory framework.

Key players in the ultrasound probe disinfection market comprise Nanosonics, Tristel plc, STERIS plc, Ecolab, Advanced Sterilization Products, Metrex Research, LLC., CIVCO Medical Solutions, CS Medical LLC, Virox, Germitec, Schulke & Mayr GmbH, and Parker Laboratories, Inc. Stay informed about this dynamic market’s developments and opportunities.

Consumables product segment holds the fastest market of the ultrasound probe disinfection market during the forecast period

By product, the ultrasound probe disinfection market is bifurcated into instruments, services, and consumables. The consumables segment is holds the fastest global ultrasound probe disinfection market during the forecast period.

Factors such as the growing demand for high-level disinfectants for critical and semi-critical ultrasound probes, and the relatively lesser capital investment needed to adopt consumables for disinfection in hospitals and diagnostic imaging centers driving the growth of this segment.

The high-level disinfection process segment accounted for the fastest market of ultrasound probe disinfection market in 2021

By process, the ultrasound probe disinfection market is bifurcated into high-level disinfection and intermediate/low-level disinfection processes. The high-level disinfection segment accounted for the fastest market of the ultrasound probe disinfection market in 2021.

The growing regulatory norms for disinfection, and the rising demand for automated disinfection systems for the high-level disinfection of TEE and endocavitary transducers are the major factors driving the demand of this segment.

Premium Insights

  • Rising Incidence of Hospital-Acquired Infections is Driving Market Growth
  • Linear Transducers Segment Accounted for the Largest Share of the APAC Market in 2020
  • China & India to Witness the Highest Growth in the Global Market During the Forecast Period

Market Overview

Market Drivers

  • Increasing Number of Ultrasound Imaging Procedures
  • Rising Incidence of Hospital-Acquired Infections due to the Improper Reprocessing of Ultrasound Probes
  • Increasing Adoption of Automated High-Level Disinfection Systems for Critical and Semi-Critical Ultrasound Probes
  • Government Regulations and Guidelines in Developed Markets
  • Technological Advancements in Ultrasound Probes

Market Restraints

  • High Cost of Automated Probe Reprocessors
  • Reluctance to Shift from Manual Disinfection Methods to Automated Probe Reprocessors

Market Opportunities

  • Increasing Birth Rates/Number of Pregnancies
  • High Growth Opportunities in Emerging Countries

Market Challenges

  • Lack of Knowledge About Probe Reprocessing
  • Inadequate Cleaning and Disinfection of Probes

Industry Trends

  • Upgradation in Technology for the Disinfection of Ultrasound Transducers
  • Increasing Number of Partnerships, Acquisitions, and Agreements in the Market

Technology Analysis

  • Manual Disinfection
  • Automated Disinfection
  • Complementary Technologies
  • Reporting Compliance and Traceability
  • Staff and Patient Safety
  • Post Disinfection Storage
  • Adjacent Technologies
  • Uv-C Hld

Company Profiles

Key Players

  • Nanosonics Ltd.
  • Tristel plc
  • Steris plc
  • Ecolab, Inc.
  • Advanced Sterilization Products
  • Metrex Research, LLC (A Part of Danaher Corporation)
  • Bode Chemie GmbH
  • Diversey Holdings, Ltd.
  • Ruhof Corporation
  • Civco Medical Solutions
  • Cs Medical LLC
  • Virox Technologies Inc.
  • Germitec S.A.
  • Schulke & Mayr GmbH
  • Parker Laboratories Inc.
  • Soluscope Sas
  • Dr. Schumacher GmbH
  • Whiteley Medical
  • Munchener Medizin Mechanik GmbH (Mmm Group)
  • Gama Healthcare Ltd.

Other Players

  • Advanced Ultrasound Solutions, Inc.
  • Ima-X
  • Pdi, Inc.
  • Borer Chemie Ag
  • Medevice Healthtech Pvt. Ltd.

For more information about this report visit here.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy